Premature vascular damage in systemic lupus erythematosus

Autoimmunity

Volumn 42, Issue 7, 2009, Pages 580-586

  Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Autoimmunity; Endothelial progenitor cells; Interferon alpha; Lupus

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; AUTOANTIBODY; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PREDNISONE;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; IMMUNE DYSREGULATION; INCIDENCE; INSULIN RESISTANCE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71049165046     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930903002479     Document Type: Review

References (91)

1. Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: An update. Nephrology (Carlton) 2005;10(2):174-179.
2. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Q J Med 1985;55(216):87-98.
3. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981;70(4):775-781.
4. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42(2):338-346.
5. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr, Jansen-McWilliams L, D' Agostino RB, and Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145(5):408-415.
6. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, and Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42(1):51-60.
7. Rahman P, Urowitz MB, GladmanDD, Bruce IN, Genest J, Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26(11):2363-2368.
8. Rajagopalan S, Somers EC,Brook RD,KehrerC, PfenningerD, Lewis E, Chakrabarti A, Richardson BC, Sheldon E, McCune WJ, and Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus:Acommon pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103(10): -13683.
9. Lima DS, Sato EI, Lima VC, Miranda F, Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29(2): -1297.
10. Pieretti J, RomanMJ, Devereux RB, LockshinMD, CrowMK, Paget JE, Schwartz L, Sammaritano L, LevineDM, and Salman JE. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007;116(4):419-426.
11. Valdivielso P, Gomez-Doblas JJ, Macias M, Haro-Liger M, Fernandez-Nebro A, Sanchez-Chaparro MA, and Gonzalez- Santos P. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008; 26(5): -1833.
12. RomanMJ,DevereuxRB,Schwartz JE,LockshinMD,PagetSA, Davis A, CrowMK, Sammaritano L, Levine DM, Shankar BA, Moeller E, and Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46(1):194-199.
13. Bruce IN, Burns RJ,GladmanDD,UrowitzMB. Single photon emission computed tomography dual isotope myocardial perfusion imaging inwomenwith systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000;27(10):2372-2377.
14. Hosenpud JD,Montanaro A, HartMV, Haines JE, Specht HD, Bennett RM, and Kloster FE. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am JMed 1984;77(2):286-292.
15. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000;50(5):397-404.
16. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MD, Schwartz JE, Paget SA, Devereux RB, and Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2399-2406.
17. RomanMJ, CrowMK, LockshinMD, Devereux RB, Paget SA, Sammaritano L, Levine DM,Davis A, and Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56(10):3412-3419.
18. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, and Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2407-2415.
19. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, and Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus:Apotential pathway for premature atherosclerosis. Blood 2007;110(8):2907-2915.
20. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-967.
21. Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, and Glover JL. Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000;31(1 Pt 1):181-189.
22. Bruno S, Bussolati B, Scacciatella P, Marra S, Sanavio F, Tarella C, and Camussi G. Combined administration of GCSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction. Cytokine 2006.
23. Bailey AS, Jiang S, Afentoulis M, Baumann CI, SchroederDA, Olson SB, Wong MH, and Fleming WH. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood 2004;103(1):13-19.
24. Chinoy MR, Miller SA, Myers RL, Cilley RE, Dillon PW. Persistent vascular defects in lung allografts attributed to defective endogenous endothelial progenitors. J Surg Res 2005;124(1):14-22.
25. Choi JH, Hur J, Yoon CH, Kim JH, Lee CS, Youn SW, Oh IY, Skurk C, Murohara T, Park YB, Walsh K, Kim HS. Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3beta activity. J Biol Chem 2004; 279(47):49430-49438.
26. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001; 70(4): -1490.
27. Moldovan L, Moldovan NI. Role of monocytes and macrophages in angiogenesis. EXS 2005;(94):127-146.
28. Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci USA 2003;100(5):2426-2431.
29. Zhang S, Jia Z, Ge J, Gong L, Ma Y, Li T, Guo J, Chen P, Hu Q, Zhang P, Liu Y, Li Z, Ma K, Li L, and Zhou C. Purified human bone marrow multipotent mesenchymal stem cells regenerate infarcted myocardium in experimental rats. Cell Transplant 2005;14(10):787-798. (Pubitemid 43152983)
30. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, and Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89(1):E1-E7.
31. Werner N, Junk S, Laufs U, Link A,Walenta K, Bohm M, and Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93(2):e17-e24.
32. Loomans CJ, De Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, De Boer HC, Verhaar MC, Braam B, Rabelink TJ, and Van Zonneveld AJ. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53(1):195-199.
33. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, and Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353(10):999-1007. (Pubitemid 41262334)
34. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger W, Wolozcszuk W, Steiner G, and Smolen JS. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005;111(2):204-211.
35. Awad O, Jiao C, Ma N, Dunnwald M, Schatteman GC. Obese diabetic mouse environment differentially affects primitive and monocytic endothelial cell progenitors. Stem Cells 2005; 23(4):575-583.
36. Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemiainduced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal 2005;7(11-12):1476-1482.
37. Chironi G, Walch L, Pernollet MG, Gariepy J, Levenson J, Rendu F, and Simon A. Decreased number of circulating CD34(+)KDR(+) cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis 2007;191:115-120
38. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Joen ES, Oh HY, and Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004;24(7): 1246-1252.
39. Zhu JH, Chen JZ, Wang XX, Xie XD, Sun J, Zhang FR. Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J Mol Cell Cardiol 2006; 40(5):648-652.
40. Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. Circ Res 2003; 93(8):e76-e86.
41. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: Limitations for therapy? Arterioscler Thromb Vasc Biol 2006;26(2):257-266.
42. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92(24):11190-11194.
43. Dimmeler S, Vasa-Nicotera M. Aging of progenitor cells: Limitation for regenerative capacity? J Am Coll Cardiol 2003; 42(12):2081-2082.
44. Di Stefano R, Santoni T, Barsotti MC, Armani C, Chifenti B, Guida C, Vanacore R, LocciMT, Mariani M, and Balbarini A. Different growth conditions for peripheral blood endothelial progenitors. Cardiovasc Radiat Med 2002;3(3-4):172-175.
45. YinAH, Miraglia S, Zanjani ED, Almeida-PoradaG, OgawaM, Leary AG, Olweus J, Kearney J, and Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90(12):5002-5012.
46. Grisar J, Steiner CW, BonelliM, Karonitsch T, Schwarzinger I, Weigel G, Steiner G, and Smolen JS. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 2008; 47(10):1476-1483.
47. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, and Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56(11):3759-3769.
48. Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent Systemic Lupus Erythematosus. Ann Rheum Dis 2007;66:865-870
49. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999;18(14):3964-3972. (Pubitemid 29335849)
50. Beaudry P, Force J, Naumov GN,Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, and Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005;11(9):3514-3522.
51. Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA 2002;99(18):11951-11956.
52. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25(3):383-392. (Pubitemid 44354221)
53. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, and Casanova JL. Inborn errors of interferon (IFN)-mediated immunity in humans: Insights into the respective roles of IFNalpha/ beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008;226:29-40.
54. Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine 2008;43(3):336-341.
55. Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16(5):541-547.
56. KirouKA, LeeC,George S,Louca K,PetersonMG,CrowMK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52(5):1491-1503.
57. BlancoP,PaluckaAK,GillM,PascualV,BanchereauJ. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294(5546): 1540-1543.
58. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, SantiL, and NoonanDM.Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 2000;156(4):1381-1393.
59. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesisrelated genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5(10):2726-2734.
60. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 1992;89(19):9049-9053.
61. Lara PN, Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P,Wun T, Gosselin I, Galvin PH, Gumerlock PH, Lenz HJ, Doroshow JH, andGandaraDR.SU5416 plus interferon alpha in advanced renal cell carcinoma: A phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003;9(13):4772-4781.
62. Leibovitch I, Loewenstein A, Alster Y, Rosenblatt I, Lazar M, Yassur Y, and Rubinstein A. Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. Ophthalmic Surg Lasers Imaging 2004; 35(1):16-22.
63. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-1463.
64. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999;103(6 Pt 1):1145-1149.
65. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, Chiarion-Sileni V, and Monfardini S. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol 2005;53(3):253-265.
66. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983;131(3):1300-1305.
67. Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, and Liu KD. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005;131(3): -1178.
68. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferonalpha: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(Suppl 1):85-93.
69. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, and Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95(6):437-448.
70. Halaas O, Liabakk NB, Vik R, Beninati C, Henneke P, Sundan A, and Espevik T. Monocytes stimulated with group B streptococci or interferons release tumour necrosis factorrelated apoptosis-inducing ligand. Scand J Immunol 2004; 60(1-2):74-81.
71. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, and Cassatella MA. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosisinducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103(10):3837-3844.
72. Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 2006; 43(5):1074-1083.
73. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114(23): -12489.
74. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116(18):2043-2052.
75. Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, and Harats D. Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med 2003;14(8):479-483.
76. Pammer J, Reinisch C, Birner P, Pogoda K, Sturzl M, Tschachler E. Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest 2006; 86(10):997-1007.
77. Gerber SA, Pober JS. IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 2008;181(2):1052-1062.
78. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, and Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54(8):2541-2549.
79. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, and Stein CM. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potentialmechanisms. Arthritis Rheum 2008;58(7):2105-2112.
80. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, and Whitehead AS. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54(7):2220-2227.
81. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson- Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46(11):2957-2963.
82. de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfa E. Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004;50(11):3610-3615.
83. Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, Antonini-Canterin F, Di Salvo G, De Gennaro Colonna V, La Carrubba S, Carerj S, and Turiel M. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:281-286
84. Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, Garofalo T, Profumo E, Rigano R, Siracusano A, Alessandri C, Salvati B, Valesini G, MalorniW, Sorice M, and Ortona E. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 2008;111(9):4559-4570.
85. Belizna CC, Richard V, Thuillez C, Levesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 2007;7(1):46-51.
86. Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, FaccoM,GuglielminiG,BoscaroE,MezzasaomaAM,MomiS, and Pengo V. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2008.
87. Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986; 37(6): -1432.
88. Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 1986;80(5):925-929.
89. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, and Reveille JD. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66(9):1168-1172. (Pubitemid 47309732)
90. Sachet JC, Borba EF, Bonfa E, Vinagre CG, Silva VM, Maranhao RC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007;16(4):273-278.
91. Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: Results of animal and human studies. Ann N Y Acad Sci 2007;1110:209-221.